Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021

Rhea-AI Summary

Curis, a biotechnology company focused on cancer therapeutics, will release its first quarter 2021 financial results on May 12, 2021, after US market close. A conference call is scheduled for 4:30 pm ET on the same day to discuss the results. The company is engaged in multiple collaborations and clinical trials, including CA-4948 for non-Hodgkin lymphoma and other conditions, as well as ongoing trials for CI-8993. Investors can access the call via phone or the Curis website.

Positive

• Scheduled release of first quarter 2021 financial results, indicating transparency.
• Active participation in multiple clinical trials, enhancing potential growth.

Negative

• None.

LEXINGTON, Mass., May 5, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2021 financial results on Wednesday, May 12, 2021, after the close of US markets. Management will host a conference call on the same day at 4:30 pm ET.

To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 pm ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma both as a monotherapy and in combination with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2021-financial-results-and-hold-conference-call-on-may-12-2021-301283970.html

SOURCE Curis, Inc.

FAQ

When will Curis release its first quarter 2021 financial results?

Curis will release its first quarter 2021 financial results on May 12, 2021, after US market close.

What time is the Curis conference call on May 12, 2021?

The conference call is scheduled for 4:30 pm ET on May 12, 2021.

How can I access the Curis financial results conference call?

You can access the call by dialing (888) 346-6389 from the US or (412) 317-5252 from other locations, or by visiting the Curis website in the 'Investors' section.